Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma

Cesar Gentille, Humaira Sarfraz, Jitesh Joshi, Jasleen Randhawa, Shilpan Shah, Sai Ravi Pingali

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. Aim: We report outcomes of Bv-ICE in CD30 (+) and Ro-ICE in CD30 (−) R/R PTCL treated in “Blinded for peer review” Cancer Center. Methods and Results: We retrospectively identified R/R PTCL patients treated with BV-ICE or romidepsin-ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv-ICE and 7 with Ro-ICE. Bv-ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro-ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv-ICE and three treated with Ro-ICE received transplantation. Conclusion: In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.

Original languageEnglish (US)
JournalCancer Reports
DOIs
StateAccepted/In press - 2022

Keywords

  • brentuximab vedotin
  • ICE
  • relapsed/refractory PTCL
  • romidepsin
  • salvage chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma'. Together they form a unique fingerprint.

Cite this